Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE phase 3 trial of gaboxadol in children with Angelman syndrome
MOH_2019-09-10_007395Phase 3Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Angelman syndrome (AS) comparing gaboxadol with placebo (2 arms). Planned start Aug 2019; status: not yet recruiting.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on MOH_2019-09-10_007395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-10_007395.